山东医药2016，Vol.56Issue(8)：17-19,后插1,4.DOI:10.3969/j.issn.1002-266X.2016.08.006
非小细胞肺癌患者血浆miR-10b、miR-122、miR-16和miR-183水平及其与总生存期的关系
Plasma levels of miR-10b, miR-122, miR-16 and miR-183 in patients with non-small-cell lung cancer and their relationships with the overall survival
摘要
Abstract
Objective To observe the levels of miR-10b, miR-122, miR-16 and miR-183 in patients with non-small-cell lung cancer (NSCLC) and to explore their relationships with the overall survival .Methods According to recurrence, 40 NSCLC patients were divided into two groups:non-recurrence group (n=8) and recurrence group (n=32).The ex-pression levels of 4 miRNAs were detected by real time quantitative PCR .NSCLC patients were divided into the high miR-NA expression group and low expression group according to the mean value of miRNAs expression .Kaplan-Meier survival a-nalysis and Cox regression were performed to determine the associations between different levels of miRNAs expression and overall survival ( OS) .Results The expression of miR-183 was higher in the non-recurrence group as compared with that of the recurrence group (P<0.05).The OS of patients with low miR-183 expression level was higher than that with high miR-183 expression (P<0.05), and there was no significant difference in the OS of patients with different miRNA expres -sion levels (all P>0.05).Cox proportional hazard regression showed that miR-183 was the independent risk factor for the overall survival of NSCLC patients (HR=2.854, 95%CI=1.154-7.055, P<0.05).Conclusion The plasma level of miR-183 in patients with NSCLC is related to the overall survival , but plasma levels of miR-10b, miR-122 and miR-16 are not associated with the overall survival of patients.关键词
非小细胞肺癌/微小核糖核酸/总生存期Key words
non-small-cell lung cancer/microRNA/overall survival分类
医药卫生引用本文复制引用
王富民,张寰,曲金力,钱碧云..非小细胞肺癌患者血浆miR-10b、miR-122、miR-16和miR-183水平及其与总生存期的关系[J].山东医药,2016,56(8):17-19,后插1,4.基金项目
国家自然科学基金资助项目(81573231) （81573231）
天津市应用基础与前沿技术研究计划(13JCYBJC23100). （13JCYBJC23100）
